Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders

Open access
Bareggi, Silvio R., Cornelli, Umberto·2012·CNS Neuroscience & Therapeutics

Abstract

SUMMARY: Clioquinol was produced as a topical antiseptic and marketed as an oral intestinal amebicide in 1934, being used to treat a wide range of intestinal diseases. In the early 1970s, it was withdrawn from the market as an oral agent because of its association with subacute myelo‐optic neuropathy (SMON), a syndrome that involves sensory and motor disturbances in the lower limbs and visual changes. The first methods for determining plasma and tissue clioquinol (5‐chloro‐7‐iodo‐8‐quinolinol) levels were set up in the 1970s and involved HPLC separation with UV detection, these were followed by a more sensitive GC method with electron capture detection and a gaschromatographic‐massspectrometric (GC‐MS) method. Finally, an HPLC method using electrochemical detection has proved to be as highly sensitive and specific as the GC‐MS. In rats, mice, rabbits, and hamsters, clioquinol is rapidily absorbed and undergoes first‐pass metabolization to glucuronate and sulfate conjugates; the concentrations of the metabolites are higher than those of free clioquinol. Bioavailabilty versus intraperitoneal dosingis about 12%. Dogs and monkeys form fewer conjugates. In man, single‐dose concentrations are dose related, and the drug's half‐life is 11–14 h. There is no accumulation, and the drug is much less metabolized to conjugates. Clioquinol acts as a zinc and copper chelator. Metal chelation is a potential therapeutic strategy for Alzheimer's disease (AD) because zinc and copper are involved in the deposition and stabilization of amyloid plaques, and chelating agents can dissolve amyloid deposits in vitro and in vivo . In general, the ability of clioquinol to chelate and redistribute metals plays an important role in diseases characterised by Zn, Cu, Fe dyshomeostasis, such as AD and Parkinson's disease, as it reduces oxidation and the amyloid burden. Zinc chelators may also act as anticancer agents. Animal toxicity studies have revealed species‐specific differences in neurotoxic responses that are related to the serum levels of clioquinol and metabolites. This is also true in humans, who form fewer conjugates. The results of studies of Alzheimer patients are conflicting and need further confirmation. The potential therapeutic role of the two main effects of MPACs (the regulation of the distribution of metals and antioxidants) has not yet been fully explored.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1755-5949.2010.00231.x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 46

  1. Tateishi J, 2000, Subacute myelo‐optic‐neuropathy: Clioquinol intoxication in humans and animals, Neuropathology, 20, 520, 10.1046/j.1440-1789.2000.00296.x · DOI
  2. 10.1016/S0140-6736(71)92699-7 · DOI
  3. Gilland O, 1984, A neurological evaluation of purported cases of SMON in Sweden, Acta Neurol Scand Suppl, 100, 165
  4. 10.1126/science.290.5495.1273a · doi:10.1126/science.290.5495.1273a
  5. Meade TW, 1975, Subacute myelo‐optic neuropathy and clioquinol, Br J Prev Soc Med, 29, 157
  6. 10.1111/j.1749-6632.2000.tb06938.x · DOI · Paper page
  7. Huckle R, 2005, PBT‐1 Prana Biotechnology, Curr Opin Invest Drugs, 6, 99
  8. 10.3233/JAD-2008-15208 · DOI · Paper page
  9. 10.1016/S0378-4347(00)86047-8 · doi:10.1016/s0378-4347(00)86047-8
  10. 10.1248/bpb1978.6.881 · DOI
  11. 10.1016/S0378-4347(00)85072-0 · doi:10.1016/s0378-4347(00)85072-0
  12. 10.1002/jps.2600621204 · doi:10.1002/jps.2600621204
  13. 10.1248/cpb.24.2007 · doi:10.1248/cpb.24.2007
  14. 10.1007/BF00295093 · DOI
  15. 10.1016/S0731-7085(01)00504-0 · doi:10.1016/s0731-7085(01)00504-0
  16. 10.1016/j.jchromb.2006.04.014 · DOI
  17. 10.1248/cpb.24.2007 · doi:10.1248/cpb.24.2007
  18. 10.1248/cpb.24.2589 · doi:10.1248/cpb.24.2589
  19. 10.1248/cpb.24.2603 · doi:10.1248/cpb.24.2603
  20. 10.1211/jpp.59.3.0008 · doi:10.1211/jpp.59.3.0008
  21. 10.1002/jps.2600731011 · doi:10.1002/jps.2600731011
  22. Committee on Drugs, 1990, Clioquinol (lodochlorhydroxyquin, Vioform) and lodoquinol (Diiodohydroxyquin): Blindness and Neuropathy, Pediatrics, 86, 797, 10.1542/peds.86.5.797 · DOI
  23. 10.1016/S0166-2236(03)00067-5 · DOI · Paper page
  24. Igata A, 1970, On the green pigment found in SMON patients: Two cases excreting greenish urine, Jap Med J, 2427, 25
  25. Takasu T, 1970, On the green tongue observed in SMON patients, Igakuno Ayumi, 72, 539
  26. 10.1016/j.toxlet.2008.08.015 · DOI
  27. Lee JY, 1999, Histochemically reactive zinc in plaques of the Swedish mutant beta‐amylodosis precursor protein transgenic mice, J Neurosci, 19, RC10, 10.1523/JNEUROSCI.19-11-j0002.1999 · DOI
  28. 10.1073/pnas.94.18.9866 · DOI · Paper page
  29. 10.1016/S0006-8993(99)02096-X · DOI · Paper page
  30. 10.1007/s00249-007-0244-1 · DOI
  31. 10.1074/jbc.M407410200 · DOI
  32. 10.1073/pnas.0404349101 · DOI · Paper page
  33. 10.1111/j.1471-4159.2009.05880.x · DOI
  34. Takasu T, 2003, SMON – a model of the iatrogenic disease, Rinsho Shinkeigaku, 43, 866
  35. Benvenisti‐Zarom L, 2004, The oxidative neurotoxicity of clioquinol, Neuro Pharmac, 49, 687
  36. 10.1016/j.tibs.2006.06.006 · DOI
  37. 10.1007/s11259-006-0054-4 · doi:10.1007/s11259-006-0054-4
  38. 10.1016/j.brainres.2009.05.031 · DOI
  39. Brown DR, 2005, Neurodegeneration and oxidative stress: Prion disease results from loss of antioxidant defence, Folia Neuropathol, 43, 229
  40. 10.1007/s11259-005-0055-8 · DOI
  41. 10.3181/0903-MR-104 · DOI
  42. 10.1196/annals.1306.004 · DOI · Paper page
  43. Ding W‐Q, 2005, Anticancer activity of the antibiotic Clioquinol, Cancer Res, 65, 3389, 10.1158/0008-5472.CAN-04-3577 · DOI · Paper page
  44. 10.1016/j.canlet.2008.06.011 · DOI
  45. 10.1254/jjp.78.55 · doi:10.1254/jjp.78.55
  46. Sampson EL, 2007, Metal protein attenuating compounds for the treatment of Alzheimer's disease, Cochrane Database Syst Rev, 3

Cited by

See all 243

Metadata

Authors
Bareggi, S. R., & Cornelli, U.
Venue
CNS Neuroscience & Therapeutics
Publisher
Wiley
Published
2010-12-27
Volume
18
Issue
1
Pages
41-46
ISSN
  • 1755-5930 (ISSN-L)
  • 1755-5949
OpenAlex
W1488741256
Cited by
243
References
13
FWCI
4.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders. https://app.cochat.ai/papers/10.1111/j.1755-5949.2010.00231.x
The paper
Bareggi, S. R., & Cornelli, U. (2012). Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2010.00231.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.